LEO 90105 clinical trials
Also written LEO 90105.
How each study uses LEO 90105 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- LEO 90105
- 3
Studies by the year they started
4 studies that test it; most in 2011 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses LEO 90105 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- LEO 90105 Ointment in Japanese Subjects With PsoriasisCompletedPhase 3LEO PharmaNCT01422434Written as LEO 90105 = calcipotriol + betamethasone dipropionateHow we know
- The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Extensive Psoriasis VulgarisCompletedPhase 1/2LEO PharmaNCT01768013Written as LEO 90105How we know
- A Study Evaluating Skin Irritation, Phototoxicity and Safety After Administration of LEO 90105 on Intact Skin of Healthy Japanese Male SubjectsCompletedPhase 1LEO PharmaNCT01293357Written as LEO 90105How we know
- A Study Evaluating the Safety of LEO 90105 and Its Vehicle, After Multiple Administration on Intact Skin of Healthy Japanese Male SubjectsCompletedPhase 1LEO PharmaNCT01293383Written as LEO 90105How we know